Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

International Journal of Hematology

Volumn 97, Issue 6, 2013, Pages 804-807

  Lee, Yoo Jin ^a   Moon, Joon Ho ^a   Shin, Ho Cheol ^a   Seo, Jong Won ^a   Han, Seo Ae ^a   Seo, Sang Kyeong ^a   Sohn, Sang Kyun ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Chronic myelogenous leukemia; Essential thrombocythemia; JAK2 V617F mutation; Myeloproliferative disease

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BCR ABL PROTEIN; HEMOGLOBIN; HYDROXYUREA; IMATINIB; NILOTINIB;

ADULT; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; ERYTHROCYTOSIS; FEMALE; GENE; GENE MUTATION; GENERALIZED EDEMA; HUMAN; HUMAN TISSUE; JAK2 V617F GENE; KARYOTYPE; LEUKOCYTOSIS; RASH; REAL TIME POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOSIS; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84879176180     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1326-8     Document Type: Article

References (22)

1. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 2011;25(3):463-72.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61.
3. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-1.
4. Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22(5):1059-62.
5. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21(5):1103-4.
6. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109(9):4106-7.
7. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008;32(10):1608-10.
8. Bornhauser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, et al. Concurrent JAK2 (V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21:1824-6.
9. Busche G, Hussein K, Bock O, Kreipe H. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8:863-4.
10. Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008;22(7):1454-5.
11. Cappetta M, Pérez V, Zubillaga MN, Elizondo V, Manrique G, Prosper I, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol. 2013;35(1):e4-5.
12. Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, et al. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol. 2012;21(3):176-83.
13. Xiao X, Zhang Y, Zhang GS, Zheng WL, Xiao L, Liu SF. Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia. Acta Haematol. 2012;127(1):47-9.
14. Toogeh G, Ferdowsi S, Naadali F, Alimoghaddam K, Ghavamzadeh A, Shirkoohi R, et al. Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera. Med Oncol. 2011;28(4):1555-8.
15. Tefferi A, Levitt R, Lasho TL, Knudson RA, Ketterling RP. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol. 2010;85(1):86-7.
16. Caocci G, Atzeni S, Orrù N, Littera R, Culurgioni F, Marongiu F, et al. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. Leuk Res. 2010;34(1):e27-9.
17. Pardini S, Fozza C, Contini S, Rimini E, Ottaviani E, Amabile M, et al. A case of coexistence between JAK2V617F and BCR/ABL. Eur J Haematol. 2008;81(1):75-6.
18. Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, et al. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res. 2008;32(6):993-5.
19. Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, et al. JAK2-V617F mutation in a patient with Philadelphia chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8:658-60.
20. Lisa P, Ambra S, Barbara S, Umberto O, Silvia B, Alberto B, et al. Concomitant occurrence of BCR-ABL and JAK2-V617F mutation. Blood. 2011;118:3445-6.
21. Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet. 1996;89(1):74-6.
22. Stoll DB, Peterson P, Exten R, Laszlo J, Pisciotta AV, Ellis JT, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol. 1988;27(2):77-83.